Literature DB >> 14961070

T-cell response to adenovirus hexon and DNA-binding protein in mice.

T McKelvey1, A Tang, A J Bett, D R Casimiro, M Chastain.   

Abstract

The successful development of adenovirus vectors for vaccines and gene therapy will require a better understanding of the host immune response. Using the ELISPOT assay to measure IFN-gamma-secreting CD8(+) cells, we identify immunodominant epitopes of the adenovirus hexon and DNA-binding protein in BALB/c and C57BL/6 mice. The T-cell response to the intramuscular administration of adenovirus serotype 5 peaks within a few weeks and gradually declines but is still detectable after 12 weeks. A second administration did not substantially increase the number of reactive T cells. The CD8(+) T-cell response was also similar between wild type and E1-deleted adenovirus. When B-cell-deficient mice were injected with adenovirus encoding the gene for secreted alkaline phosphatase, sera phosphatase activity was reduced more quickly in mice pre-exposed to adenovirus. These results add to the evidence that cell-mediated immunity is a substantial barrier to therapeutic adenoviral vectors and provide more quantitative tools to measure cellular immune responses to adenovirus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14961070     DOI: 10.1038/sj.gt.3302232

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  20 in total

1.  Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.

Authors:  Nicole Frahm; Allan C DeCamp; David P Friedrich; Donald K Carter; Olivier D Defawe; James G Kublin; Danilo R Casimiro; Ann Duerr; Michael N Robertson; Susan P Buchbinder; Yunda Huang; Gregory A Spies; Stephen C De Rosa; M Juliana McElrath
Journal:  J Clin Invest       Date:  2011-12-27       Impact factor: 14.808

Review 2.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

3.  Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.

Authors:  Adam E Snook; Michael S Magee; Glen P Marszalowicz; Stephanie Schulz; Scott A Waldman
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

4.  Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice.

Authors:  Norman Woller; Sarah Knocke; Bettina Mundt; Engin Gürlevik; Nina Strüver; Arnold Kloos; Bita Boozari; Peter Schache; Michael P Manns; Nisar P Malek; Tim Sparwasser; Lars Zender; Thomas C Wirth; Stefan Kubicka; Florian Kühnel
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

5.  Immune reactivity after adenoviral-mediated aquaporin-1 cDNA transfer to human parotid glands.

Authors:  I Alevizos; C Zheng; A P Cotrim; C M Goldsmith; L McCullagh; T Berkowitz; S L Strobl; A Malyguine; W C Kopp; J A Chiorini; N P Nikolov; M Neely; G G Illei; B J Baum
Journal:  Oral Dis       Date:  2017-02-08       Impact factor: 3.511

6.  Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment.

Authors:  Candace S Hayes; Allyson C Shicora; Martin P Keough; Adam E Snook; Mark R Burns; Susan K Gilmour
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

7.  Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.

Authors:  Adam E Snook; Michael S Magee; Stephanie Schulz; Scott A Waldman
Journal:  Eur J Immunol       Date:  2014-05-21       Impact factor: 5.532

8.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

9.  Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses.

Authors:  Graeme E Price; Mark R Soboleski; Chia-Yun Lo; Julia A Misplon; Mary R Quirion; Katherine V Houser; Melissa B Pearce; Claudia Pappas; Terrence M Tumpey; Suzanne L Epstein
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

10.  Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.

Authors:  A Sharma; M Tandon; Y S Ahi; D S Bangari; R Vemulapalli; S K Mittal
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.